echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > JNNP: Plasma Aβ as a biomarker for predicting Aβ-PET findings in Alzheimer's disease patients

    JNNP: Plasma Aβ as a biomarker for predicting Aβ-PET findings in Alzheimer's disease patients

    • Last Update: 2022-04-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Alzheimer's disease (AD) is a neurodegenerative disease characterized by abnormal accumulation of amyloid beta (aβ) and hyperphosphorylation of tau protein


    Fortunately, long-term presymptomatic stages of AD make it possible to intervene early with disease-modifying therapies


    Currently, Aβ pathology can be identified by biomarker levels of amyloid-β positron emission tomography (Aβ-PET)


    Patients assessed using Aβ-PET scans and plasma Aβ were included in this meta-analysis by searching online databases, including Embase, PubMed, and the Cochrane library


    Patients assessed using Aβ-PET scans and plasma Aβ were included in this meta-analysis by searching online databases, including Embase, PubMed, and the Cochrane library


    The meta-analysis included 16 studies with a total of 3047 participants


    The meta-analysis included 16 studies with a total of 3047 participants


    Meta-analysis results of Aβ40 group

    Meta-analysis results of Aβ40 group

    In this meta-analysis, it was found that plasma Aβ40 values ​​may not differ between PET (+) and PET (−)


    In this meta-analysis, it was found that plasma Aβ40 values ​​may not differ between PET (+) and PET (−)


    Egger'stest results in Aβ40 group

    Egger's 

    This meta-analysis provides evidence that plasma Aβ40 values ​​may not discriminate between PET(+) and PET(−) people.


    ChengL ,LiW ,ChenY Cheng  LCheng Li  WLi Chen  YChen, et alPlasma Aβ as a biomarker for predicting Aβ-PET status in Alzheimer's disease: a systematic review with meta-analysisJournal of Neurology, Neurosurgery & Psychiatry  Published Online First:  03 March 2022.
     Published Online First: doi:  10.
    1136/jnnp-2021-327864doi:

    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.